eClinical Tech News

Marvel Biosciences has secured financial and strategic backing from 5 Horizons Ventures to initiate a Phase I study of...

CAMP4 Therapeutics has appointed Michael MacLean to its board of directors as the company readies CMP-002, an antisense oligonucleotide...

Serina Therapeutics has opened a Phase 1b clinical trial of SER-252, a subcutaneous apomorphine candidate built on the company’s...

Exicure reported 2025 results that underscore a high-stakes pivot and an urgent need for capital. Cash fell to $3.7...

Serina Therapeutics has secured FDA IND clearance for SER-252 and initiated dosing in a randomized Phase 1b study in...

Humacyte reported fourth-quarter and full-year 2025 results alongside a string of commercialization and regulatory moves for its bioengineered vessel...

Genfit reported full-year 2025 results and a 2026 outlook that pivots the company from a single‑asset story to a...

Adagene reported 2025 results and advanced its lead program, muzastotug (ADG126), a masked anti-CTLA-4 antibody now showing dose-dependent activity...

Nanobiotix has extended its cash runway into early 2028 and tightened strategic alignment around its lead asset, JNJ-1900 (formerly...

Nanobiotix closed 2025 with a materially de-risked operating plan and a clearer development arc for its radioenhancer JNJ-1900 (formerly...